Equateq has synthesized omega-6 dihomma-gamma-linolenic acid (DGLA) for research, pharmaceutical and cosmetic use, especially for anti-inflammatory benefits. According to the company, this is the first time omega-6 DGLA has been synthesized. The ingredient, EQT-101, is the first commercialized initiative derived from the company's lipid synthesis program.
DGLA is said to perform as a sister fatty acid to omega-3 eicosapentaenoic acid (EPA), which is a hormone-like substance that can regulate cell function and provide anti-inflammatory functions. DGLA provides anti-inflammatory benefits due to its ability to create prostaglandin E1 and 15-HETrE. Therefore, DGLA could be used to treat conditions such as eczema, psoriasis, asthma and arthritis.
According to the company, since DGLA is typically found in human breast milk and some organs and glands, it is difficult to source from nature. Previously, GLA was derived from evening primrose and borage oils, which can convert into DGLA in the body. However, the company has mimicked processes in the human body to produce up to 98% pure DGLA. The synthesized omega-6 DGLA is recommended as an active ingredient in topical treatments for skin conditions.